GLPwatch
Papers (10376)
Page 78 of 173, ranked by citation count.
- Pharmacotherapy for obesity.
- Effectiveness, persistence of use, and safety of orlistat and liraglutide in a group of patients with obesity.
- Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review.
- GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.
- Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.
- Glucagon like-peptide 1 receptor and the liver.
- 10-fold liraglutide overdose over 7 months resulted only in minor side-effects.
- GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
- New association of bone morphogenetic protein 4 concentrations with fat distribution in obesity and Exenatide intervention on it.
- Albumin as a drug delivery and diagnostic tool and its market approved products.
- Medicinal Plants Qua Glucagon-Like Peptide-1 Secretagogue via Intestinal Nutrient Sensors.
- Application of Af4-Multidetection to Liraglutide in Its Formulation: Preserving and Representing Native Aggregation.
- LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
- Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats.
- Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.
- Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection.
- Effectiveness and safety of liraglutide after three years of treatment.
- Treatment of insulin resistance with tirzepatide leading to improvement of hair loss.
- Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
- Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.
- Glutamine up-regulates pancreatic sodium-dependent neutral aminoacid transporter-2 and mitigates islets apoptosis in diabetic rats.
- Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.
- The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells.
- Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.
- Real-World Impact of GLP-1 Receptor Agonists on Endoscopic Patient Outcomes in an Ambulatory Setting: A Retrospective Study at a Large Tertiary Center.
- Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
- Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.
- Hepatic portal vein denervation impairs oral glucose tolerance but not exenatide's effect on glycemia.
- Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.
- The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.
- Monotreme glucagon-like peptide-1 in venom and gut: one gene - two very different functions.
- Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.
- Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials.
- Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
- Pharmacological Treatment of Obesity in Older Adults.
- Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment.
- Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
- Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-S.
- The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
- Weight and Glycemic Control Outcomes of Bariatric Surgery and Pharmacotherapy in Patients With Melanocortin-4 Receptor Deficiency.
- Exendin-4 regulates endoplasmic reticulum stress to protect endothelial progenitor cells from high-glucose damage.
- Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice.
- Evaluation of Patient-Reported Satisfaction and Clinical Efficacy of Once-Weekly Semaglutide in Patients with Type 2 Diabetes: An Ambispective Study.
- Design, evaluation, and in vitro-in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide.
- Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.
- Treatment persistence in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists in clinical practice in Sweden.
- Role of glucagon-like peptide-1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts.
- Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor's anti-inflammatory effects.
- Glucagon-like peptide-1 control of GnRH secretion in female sheep.
- The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties.
- Exendin‑4 inhibits lipotoxicity‑induced oxidative stress in β‑cells by inhibiting the activation of TLR4/NF‑κB signaling pathway.
- Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.
- Glucagon-Like Peptide-1 Receptor Agonist Cases Reported to United States Poison Centers, 2017-2022.
- Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome.
- Effect of PANDER in βTC6-cell lipoapoptosis and the protective role of exendin-4.
- SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
- Tirzepatide and potential use for metabolically healthy obesity.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
- Role of ERp46 in β-cell lipoapoptosis through endoplasmic reticulum stress pathway as well as the protective effect of exendin-4.
- Hyperglycemia and adverse outcomes in acute coronary syndromes: is serum glucose the provocateur or innocent bystander?